Advus Financial Partners, LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Advus Financial Partners, LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$200K	Buy	+403	New	+$179K	0.05%	260
2025 Q3	–	Sell	-502	Closed	-$223K	–	270
2025 Q2	$223K	Buy	502 +19	+4%	+$8.76K	0.06%	230
2025 Q1	$234K	Buy	+483	New	+$225K	0.07%	214
2023 Q3	–	Sell	-920	Closed	-$324K	–	170
2023 Q2	$324K	Buy	920 +14	+2%	+$4.72K	0.12%	100
2023 Q1	$285K	Buy	906 +28	+3%	+$8.4K	0.12%	106
2022 Q4	$254K	Buy	878 +6	+0.7%	+$1.83K	0.11%	125
2022 Q3	$252K	Buy	872 +9	+1%	+$2.59K	0.13%	102
2022 Q2	$243K	Buy	863 +49	+6%	+$13.1K	0.13%	106
2022 Q1	$212K	Buy	+814	New	+$193K	0.11%	117

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Advus Financial Partners, LLC's VRTX Position: Q2 2026 in Review

Advus Financial Partners, LLC opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 403 shares worth $200K. The stake represents 0.05% of the portfolio and ranks #260 among its holdings. This is a return to the name: Advus Financial Partners, LLC previously reported a position in VRTX as recently as Q2 2025.

Advus Financial Partners, LLC first reported a position in VRTX in Q1 2022 and has held it in 9 quarters since. The position peaked at $324K in Q2 2023. 1,751 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Advus Financial Partners, LLC held 403 shares of Vertex Pharmaceuticals worth $200K as of Q2 2026.
Vertex Pharmaceuticals was a new Advus Financial Partners, LLC position in Q2 2026.
Vertex Pharmaceuticals made up 0.05% of Advus Financial Partners, LLC's portfolio in Q2 2026, its #260 holding.
Advus Financial Partners, LLC first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
Advus Financial Partners, LLC's Vertex Pharmaceuticals position peaked at $324K in Q2 2023.
1,751 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Advus Financial Partners, LLC's 13F filing for Q2 2026, filed 25 Aug 2026.